The inhibitory effect of selective cyclooxygenase-2 inhibitor NS-398 on the cholangiocarcinoma line （QBC939）

Objective： We studied the inhibitory effect of human cholangiocarcinoma line （QBC939） treated by selective cyclooxygenase-2 （COX-2） inhibitor NS-398 and provided the theoretical foundation for the clinical practice. Methods： Selec- tive COX-2 inhibitor NS-398 on the growth suppression was evaluated...

Full description

Saved in:
Bibliographic Details
Published in中德临床肿瘤学杂志：英文版 Vol. 11; no. 9; pp. 522 - 526
Main Author Youjie Fan Jingyu Cao Wende Sun Rui Han Shihai Liu
Format Journal Article
LanguageEnglish
Published 2012
Subjects
COX-2抑制剂
NS-398
环氧合酶-2
生长抑制作用
癌
胆管
血管内皮生长因子
酶联免疫吸附试验
Online AccessGet full text

Cover

More Information
Summary:Objective： We studied the inhibitory effect of human cholangiocarcinoma line （QBC939） treated by selective cyclooxygenase-2 （COX-2） inhibitor NS-398 and provided the theoretical foundation for the clinical practice. Methods： Selec- tive COX-2 inhibitor NS-398 on the growth suppression was evaluated by MTT method. The apoptotic rate was quantified and cell cycle by flow cytometry （FCM）. Invasive ability was detected by Transwell. The expression of vascular endothelial growth factor （VEGF） and COX-2 in cholangiocarcinoma line was determined by enzyme-linked immunosorbent assay （ELISA）. Results： NS-398 could be time-dose dependently inhibited the growth, induced apoptosis, invasived ability, S phase was inhibited, down-regulate the expression of VEGF and COX-2 in cholangiocarcinoma line （QBC939）. Conclusion： NS398 can inhibit proliferation of cholangiocarcinoma cell line QBC939 and inhibit the invasive ability and induce its apoptosis in vitro, which may contributed to the COX-2 dependent pathway to reduce the release of VEGF.
Bibliography:NS-398; COX-2; vascular endothelial growth factor （VEGF）; cholangiocarcinoma
Objective： We studied the inhibitory effect of human cholangiocarcinoma line （QBC939） treated by selective cyclooxygenase-2 （COX-2） inhibitor NS-398 and provided the theoretical foundation for the clinical practice. Methods： Selec- tive COX-2 inhibitor NS-398 on the growth suppression was evaluated by MTT method. The apoptotic rate was quantified and cell cycle by flow cytometry （FCM）. Invasive ability was detected by Transwell. The expression of vascular endothelial growth factor （VEGF） and COX-2 in cholangiocarcinoma line was determined by enzyme-linked immunosorbent assay （ELISA）. Results： NS-398 could be time-dose dependently inhibited the growth, induced apoptosis, invasived ability, S phase was inhibited, down-regulate the expression of VEGF and COX-2 in cholangiocarcinoma line （QBC939）. Conclusion： NS398 can inhibit proliferation of cholangiocarcinoma cell line QBC939 and inhibit the invasive ability and induce its apoptosis in vitro, which may contributed to the COX-2 dependent pathway to reduce the release of VEGF.
42-1654/R
ISSN:1610-1979
1613-9089